Cite

HARVARD Citation

    Botrus, G. et al. (2021). Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. Expert opinion on investigational drugs. pp. 309-316. [Online]. 
  
Back to record